Factors associated with early mortality among patients with De Novo metastatic breast cancer: A population-based study

Oncologist

Volumn 22, Issue 4, 2017, Pages 386-393

  Vaz Luis, Ines ^a,b   Lin, Nancy U ^a   Keating, Nancy L ^c,d   Barry, William T ^a   Winer, Eric P ^a   Freedman, Rachel A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Breast cancer subtypes; End results (SEER); Epidemiology; Metastatic breast cancer; Surveillance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DE NOVO METASTATIC BREAST CANCER; ETHNICITY; FEMALE; HUMAN; INSURANCE; MAJOR CLINICAL STUDY; MARRIAGE; METASTATIC BREAST CANCER; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RACE; TIME OF DEATH; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; METASTASIS; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE;

EID: 85017419590     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0369     Document Type: Article

References (25)

1. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
2. DeSantis C, Ma J, Bryan L et al. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64: 52-62.
3. Dawood S, Broglio K, Gonzalez-Angulo AM et al. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 2008; 26: 4891-4898.
4. Breast Cancer Facts & Figures. American Cancer Society. Available at http://www.cancer.org/ acs/groups/content/%40research/documents/document/ acspc-042725.pdf. Accessed January 20, 2017.
5. Vaz-Luis I, Lin NU, Keating NL et al. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat 2015; 151: 697-707.
6. Dawood S, Broglio K, Ensor J et al. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 2010; 21: 2169-2174.
7. Andre F, Slimane K, Bachelot T et al. Breast cancer with synchronous metastases: Trends in survival during a 14-year period. J Clin Oncol 2004; 22: 3302-3308.
8. Hortobagyi GN, Smith TL, Legha SS et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1983; 1: 776-786.
9. Yamamoto N, Watanabe T, Katsumata N et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 1998; 16: 2401-2408.
10. SEER Cancer Stat Facts: Female Breast Cancer. National Cancer Institute. Available at http://seer.cancer. gov/statfacts/html/breast.html. Accessed January 17, 2017.
11. Warren JL, Klabunde CN, Schrag D et al. Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 2002; 40: IV-3218.
12. Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-742.
13. Wilper AP, Woolhandler S, Lasser KE et al. Health insurance and mortality in US adults. Am J Public Health 2009; 99: 2289-2295.
14. Franks P, Clancy CM, Gold MR. Health insurance and mortality. Evidence from a national cohort. JAMA 1993; 270: 737-741.
15. Ayanian JZ, Kohler BA, Abe T et al. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med 1993; 329: 326-331.
16. McWilliams JM, Zaslavsky AM, Meara Eet al. Health insurance coverage and mortality among the near-elderly. Health Aff (Millwood) 2004; 23: 223-233.
17. Roetzheim RG, Gonzalez EC, Ferrante JM et al. Effects of health insurance and race on breast carcinoma treatments and outcomes. Cancer 2000; 89: 2202-2213.
18. Wan S, Jubelirer S. Geographic access and agerelated variation in chemotherapy use in elderly with metastatic breast cancer. Breast Cancer Res Treat 2015; 149: 199-209.
19. Nattinger AB, Gottlieb MS, Veum J et al. Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med 1992; 326: 1102-1107.
20. Chagpar AB, Studts JL, Scoggins CR et al. Factors associated with surgical options for breast carcinoma. Cancer 2006; 106: 1462-1466.
21. Guadagnoli E,Weeks JC, Shapiro CL et al. Use of breast-conserving surgery for treatment of stage I and stage II breast cancer. J Clin Oncol 1998; 16: 101-106.
22. Morrow M, White J, Moughan J et al. Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma. J Clin Oncol 2001; 19: 2254-2262.
23. Showalter SL, Grover S, Sharma S et al. Factors influencing surgical and adjuvant therapy in stage I breast cancer: A SEER 18 database analysis. Ann Surg Oncol 2013; 20: 1287-1294.
24. Hassett MJ, Ritzwoller DP, Taback N et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care 2014; 52: e65-e73.
25. Ries LAG, Eisner MP, Kosary CL et al, eds. SEER Cancer Statistics Review, 1975-2000. National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2000/, 2003, Accessed January 17, 2017.